Skip to content
Wednesday, November 18, 2026 · Riyadh
العربيةNewsletterContact
Saudi Arabia

Vision 2030 accelerating patient access to innovative treatments, says SFDA chief

SFDA CEO Hisham Aljadhey highlights Vision 2030’s role in speeding access to new therapies and prioritizing patient protection at a global regulatory summit.

Ajel News19 min ago · 2 min read
SFDA CEO Hisham Aljadhey speaks at global regulatory summit

Key Takeaways

AI

Hisham Aljadhey, CEO of the Saudi Food and Drug Authority, emphasized the importance of strengthening international cooperation among regulatory bodies and leveraging innovation to develop regulatory frameworks. He said these efforts help keep pace with rapid changes in the pharmaceutical sector and accelerate access to innovative treatments tailored to patient needs, especially for those with rare diseases and special therapeutic requirements.

According to an official statement from the authority, Aljadhey made these remarks during a panel discussion titled "Shared Leadership: Shaping the Future of Global Regulatory Systems through Collaboration and Regulatory Innovation," held as part of the DIA-MHRA Global Summit in London on November 16 and 17.

Aljadhey explained that, under Saudi Vision 2030, the Kingdom continues to develop an integrated and sustainable regulatory model that enhances oversight efficiency, anticipates challenges, and adapts to change. He said patient protection remains a top priority by ensuring access to safe and effective medical products that meet health needs.

He noted that the Kingdom’s progress in regulatory affairs is the result of national collaboration, investment in research and innovation, the use of emerging technologies in the development and manufacturing of biopharmaceuticals, and the expansion of data infrastructure. These efforts have strengthened the healthcare sector and improved regulatory assessment tools in line with scientific and technological advances in the pharmaceutical industry.

The authority’s participation in the summit reflects its ongoing role in enhancing Saudi Arabia’s presence in international regulatory forums and contributing to the future direction of pharmaceutical regulation. This is achieved by exchanging expertise and best practices with peer organizations and supporting innovation in medical product development, thereby improving patient safety and the availability of safe and effective treatments.